Elizabeth Evans to Adolescent
This is a "connection" page, showing publications Elizabeth Evans has written about Adolescent.
Connection Strength
0.708
-
Evans EA, Goldwater E, Stanek EJ, Brierley-Bowers P, Buchanan D, Whitehill JM. Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. J Psychoactive Drugs. 2021 Apr-Jun; 53(2):158-167.
Score: 0.084
-
Evans EA, Goff SL, Upchurch DM, Grella CE. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addict Behav. 2020 03; 102:106149.
Score: 0.077
-
Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.
Score: 0.076
-
Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017 05 01; 174:128-136.
Score: 0.065
-
Evans EA, Grella CE, Upchurch DM. Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. Soc Psychiatry Psychiatr Epidemiol. 2017 07; 52(7):901-912.
Score: 0.065
-
Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun; 110(6):996-1005.
Score: 0.056
-
Evans E, Li L, Grella C, Brecht ML, Hser YI. Developmental timing of first drug treatment and 10-year patterns of drug use. J Subst Abuse Treat. 2013 Mar; 44(3):271-9.
Score: 0.047
-
Hser YI, Huang D, Brecht ML, Li L, Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008; 27(3):13-21.
Score: 0.034
-
Barnett A, Edwards K, Harper R, Evans E, Alexander D, Choudhary M, Richards G. The Association Between Autistic Traits and Disordered Eating is Moderated by Sex/Gender and Independent of Anxiety and Depression. J Autism Dev Disord. 2021 Jun; 51(6):1866-1879.
Score: 0.022
-
Jaaniste T, Yang J, Bang J, Yee RD, Evans E, Aouad P, Champion GD. Multidimensional Self-report Assessment of Children's Acute Pain in an Inpatient Setting. Clin J Pain. 2021 06 01; 37(6):421-428.
Score: 0.022
-
Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497.
Score: 0.018
-
Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017 11; 49:32-40.
Score: 0.017
-
Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction. 2017 May; 112(5):838-851.
Score: 0.016
-
Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr; 111(4):695-705.
Score: 0.015
-
Saroyan JM, Evans EA, Segoshi A, Vosburg SK, Miller-Saultz D, Sullivan MA. Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young Adults. Clin J Pain. 2016 Jan; 32(1):1-6.
Score: 0.015
-
Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01; 61(7):1157-65.
Score: 0.014
-
Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, Rawson R, Hser YI. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend. 2014 Oct 01; 143:149-57.
Score: 0.013
-
Gill KE, Evans E, Kayser J, Ben-David S, Messinger J, Bruder G, Malaspina D, Corcoran CM. Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry Res. 2014 Dec 15; 220(1-2):201-4.
Score: 0.013
-
Hser YI, Evans E, Huang D, Brecht ML, Li L. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav. 2008 Dec; 33(12):1581-9.
Score: 0.009
-
Hser YI, Evans E, Teruya C, Huang D, Anglin MD. Predictors of short-term treatment outcomes among California's Proposition 36 participants. Eval Program Plann. 2007 May; 30(2):187-96.
Score: 0.008
-
Hser YI, Teruya C, Brown AH, Huang D, Evans E, Anglin MD. Impact of California's Proposition 36 on the drug treatment system: treatment capacity and displacement. Am J Public Health. 2007 Jan; 97(1):104-9.
Score: 0.008
-
Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004 Jul; 55(7):767-74.
Score: 0.007
-
Hser YI, Teruya C, Evans EA, Longshore D, Grella C, Farabee D. Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes. Eval Rev. 2003 Oct; 27(5):479-505.
Score: 0.006